High PEEP in Noninvasive Ventilation Patients With Pneumonia or ARDS
Key facts
- Who runs it
- Chongqing Medical University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 706 people, planned
- Started
- 4 Jan 2026
- Expected to end
- 31 Dec 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- The level of PEEP during noninvasive ventilation
- Record updated
- 7 January 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Age >18 years
- PaO2/FiO2 ≤300 mmHg or SpO2/FiO2 ≤315(SpO2 ≤97%)
- Anticipated NIV duration > 12 h
- Preserved consciousness (GCS≥13)
Who cannot take part
- Contraindications to NIV (e.g., anatomical malformations, recent pulmonary/esophageal surgery [within 7 days])
- Acute-on-chronic respiratory failure
- Congestive heart failure
- Use of NIV > 24 h before randomization
- Use of NIV after extubation (within 48 hours)
- Pneumothorax
- NIV intolerance
- Refusal to participate
- Pregnancy
- Need for emergency intubation
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Noninvasive ventilation is commonly employed in patients with pneumonia or acute respiratory distress syndrome (ARDS) and has been shown to reduce the need for intubation and invasive mechanical ventilation. However, the rate of noninvasive ventilation failure remains substantial, at approximately 40%. Compared with patients in whom noninvasive ventilation succeeds, those who experience noninvasive ventilation failure have a higher likelihood of mortality during their intensive care unit or hospital stay. Therefore, improving the success rate of noninvasive ventilation is clinically important. In patients with lung consolidation receiving invasive mechanical ventilation, high positive end-expiratory pressure (PEEP) can improve oxygenation. Noninvasive ventilation operates on similar physiological principles and can also deliver high PEEP via a mask interface. Nevertheless, there is limited evidence regarding the use of high PEEP during mask-delivered noninvasive ventilation. This study aimed to evaluate whether high PEEP can increase intubation-free survival in patients with pneumonia or ARDS who are treated with noninvasive ventilation.
The 2 groups in the trial
- High PEEP groupTreatment being tested
Patients in high PEEP group will received 10 to 15 cmH2O of PEEP during noninvasive ventilation.
Treatment: The level of PEEP during noninvasive ventilation
- Low PEEP groupExisting treatment, for comparison
Patients in low PEEP group will received 5 cmH2O of PEEP during noninvasive ventilation.
Treatment: The level of PEEP during noninvasive ventilation
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effect of High Versus Low Positive End-Expiratory Pressure on Intubation-Free Survival in Patients With Pneumonia or ARDS Receiving Noninvasive Ventilation: A Multicenter Randomized Controlled Trial
- Record updated
- 7 January 2026